Insmed Incorporated

NasdaqGS:INSM

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

Location

United States

Market Cap

USD 20.02 B

Share Price

USD 105.42

Avg Daily Volume

2,289,787

Change (1 day)

2.67%

Change (1 year)

55.05%

Change (YTD)

52.69%

Insmed Incorporated Free Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2025: USD -789.25 M

Insmed Incorporated Free Cash Flow is USD -789.25 M for the Trailing 12 Months (TTM) ending March 31, 2025, a 34.10% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Insmed Incorporated Free Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2024 was USD -588.55 M, a 29.88% change year over year.
Insmed Incorporated Free Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -453.16 M, a 30.22% change year over year.
Insmed Incorporated Free Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -347.99 M, a 17.96% change year over year.
Insmed Incorporated Free Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -295.02 M, a 7.02% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Free Cash Flow	Operating Cash Flow	Capital Expenditure	Net Cash Used For Investing Activities

NasdaqGS: INSM

Insmed Incorporated

CEO	Mr. William H. Lewis J.D., M.B.A.
IPO Date	June 1, 2000
Location	United States
Headquarters	700 US Highway 202/206
Employees	1,271
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals

Description

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.